Table 1. SHH, GLI1, GLI2, GLI3, and PTCH1 expression in human prostate cancer.
SHH
|
PTCH1
|
GLI1
|
GLI2
|
GLI3
|
||||||
---|---|---|---|---|---|---|---|---|---|---|
Patient | Fold increase | Range | Fold increase | Range | Fold increase | Range | Fold increase | Range | Fold increase | Range |
829 | 0 | 0-0.01 | 1.5 | 1.1-2.1 | 26.1 | 20.8-32.7 | 0.02 | 0.02-0.02 | 72 | 53-99 |
887 | 0.2 | 0.05-0.9 | 8.5 | 7.6-9.5 | 0.09 | 0.07-0.13 | 0.43 | 0.37-0.51 | 1.1 | 0.8-1.6 |
921 | 2.9 | 1.3-6.3 | 50 | 30-84 | 2 | 1.1-3.4 | 3.8 | 2.4-6.1 | 12.5 | 7.7-20.4 |
945 | 9.8 | 6.2-15.7 | 7.8 | 5.7-10.7 | 22.7 | 21.6-23.9 | 0.7 | 0.5-1.0 | 2.2 | 2.1-2.4 |
1854 | 4.7 | 1.8-11.7 | 213 | 164-278 | 5.1 | 3.8-6.9 | 19.5 | 10.9-35.1 | 5.7 | 4.4-7.5 |
1866 | 4.6 | 4.1-5.2 | 3.4 | 3.1-3.7 | 299 | 260-342 | 0.03 | 0.02-0.03 | 0.18 | 0.15-0.2 |
Fold increase in gene expression in tumors versus matched normal tissue determined by real-time RT-PCR analyses as calculated by the ΔCT method. Range indicates ± 1 SD. Gene expression levels were normalized to β-actin. Increases of 2-fold or more are shown in bold.